Literature DB >> 16230415

Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.

You Keun Shin1, Ji Sun Park, Hyun Seok Kim, Hyun Jung Jun, Gwi Eon Kim, Chang Ok Suh, Yeon Sook Yun, Hongryull Pyo.   

Abstract

To characterize the radiation-enhancing effects on human cancer cells and underlying mechanisms of celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, and to ascertain whether its effects are COX-2 dependent. Clonogenic cytotoxicity assays and radiation survival assays after treatment with celecoxib +/- radiation were done on four human cancer cell lines that expressed differential COX-2 levels. Stably COX-2 knocked down or overexpressed cell lines were developed, and clonogenic assays, apoptosis assays, or cell cycle change measurements were conducted after treatment with celecoxib +/- radiation. Prostaglandin E(2) (PGE2) was applied to medium after treatment with celecoxib +/- radiation to determine whether the radiation-enhancing effect associated with celecoxib results from reduced generation of prostaglandin. Celecoxib's radiation-enhancing effect was observed in COX-2-expressing A549 and NCI-H460 cells but was not observed in the COX-2 nonexpressing MCF-7 and HCT-116 cells. Celecoxib's radiation-enhancing effects in A549 cells were shown to disappear after the administration of COX-2 knocked down. In contrast, the HCT-116 cells were radiosensitized by celecoxib after being transfected with COX-2 expression vector. The addition of PGE2 after treatment with celecoxib +/- radiation had no significant effects on celecoxib's radiation-enhancing effects in A549 and COX-2 transfected HCT-116 cells. Radiation-induced G2-M arrest was enhanced and sustained in the COX-2-overexpressing cells compared with that seen in COX-2 low-expressing cells. Celecoxib or NS-398 effected no changes or attenuated radiation-induced G(2)-M arrest in the COX-2-overexpressing cells but further enhanced the radiation-induced G(2)-M arrest in the COX-2 low-expressing cells. Celecoxib's radiation-enhancing effects seem to occur in a COX-2 expression-dependent manner in the cancer cells. This effect does not seem to be the result of reduced PGE2 generation. Celecoxib may exert an inhibitory effect on enhanced radiation-induced G2-M arrest in the COX-2-overexpressing cells, which may allow the arrested cells to enter mitosis and die after radiation, but may also further enhance radiation-induced G2-M arrest in the COX-2 low-expressing cells, by virtue of another mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230415     DOI: 10.1158/0008-5472.CAN-05-0220

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.

Authors:  Young-Mee Kim; Hongryull Pyo
Journal:  DNA Cell Biol       Date:  2011-08-10       Impact factor: 3.311

Review 2.  Cyclooxygenases in hepatocellular carcinoma.

Authors:  Melchiorre Cervello; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

Authors:  Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

4.  Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.

Authors:  Chen Chen; Hui Ling Shen; Jing Yang; Qiao Yun Chen; Wen Lin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-14       Impact factor: 4.553

5.  Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP.

Authors:  Xiao-Ting Xu; Wen-Tao Hu; Ju-Ying Zhou; Yu Tu
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

6.  Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.

Authors:  Soo-Yeon Park; Young Mee Kim; Hongryull Pyo
Journal:  Mol Cancer       Date:  2010-08-23       Impact factor: 27.401

7.  Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

Authors:  Shibo Fu; Michael Rivera; Eric C Ko; Andrew G Sikora; Chien-Ting Chen; Ha Linh Vu; David Cannan; Samuel Eisenstein; Barry S Rosenstein; Julio Aguirre-Ghiso; Shu-Hsia Chen; Johnny Kao
Journal:  J Cell Sci Ther       Date:  2011-10-13

8.  Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

Authors:  Chih-Long Chang; Barbara Ma; Xiaowu Pang; T-C Wu; Chien-Fu Hung
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

9.  Different cell cycle modulation by celecoxib at different concentrations.

Authors:  Young-Mee Kim; Hongryull Pyo
Journal:  Cancer Biother Radiopharm       Date:  2012-12-26       Impact factor: 3.099

10.  Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.

Authors:  Ninib Baryawno; Baldur Sveinbjörnsson; Staffan Eksborg; Abiel Orrego; Lova Segerström; Carl Otto Oqvist; Stefan Holm; Bengt Gustavsson; Bertil Kågedal; Per Kogner; John Inge Johnsen
Journal:  Neuro Oncol       Date:  2008-08-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.